Production (Stage)
Aurinia Pharmaceuticals Inc.
AUPH
$7.98
-$0.175-2.15%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 163.69% | 107.37% | 70.78% | 30.78% | 35.34% |
| Total Depreciation and Amortization | 23.31% | 66.95% | 182.38% | 707.67% | 510.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -53.41% | -64.32% | 12.22% | 8.08% | -5.71% |
| Change in Net Operating Assets | -181.32% | 197.15% | -65.36% | -88.57% | -97.15% |
| Cash from Operations | 415.30% | 232.66% | 176.59% | 95.64% | 68.37% |
| Capital Expenditure | 22.19% | 59.19% | 43.76% | 70.49% | 31.61% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 18.33% | 760.57% | -102.71% | 54.51% | 1.38% |
| Cash from Investing | 19.21% | 685.48% | -79.35% | 54.84% | 2.45% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 6.41% | -19.59% | -345.20% | -- | -- |
| Issuance of Common Stock | 67.56% | 105.83% | 118.52% | 217.36% | 201.58% |
| Repurchase of Common Stock | -347.93% | -2,175.95% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -282.12% | -856.96% | -2,886.17% | -1,000.87% | -695.04% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 108.02% | 176.29% | 76.66% | 30.93% | 43.63% |